27284958|t|Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies
27284958|a|Activating, nonamplification ERBB2 mutations (ERBB2mut) are not detected by immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH), but are detected by DNA sequencing and may predict clinical responses to human epidermal growth factor receptor (HER2)- targeted therapy. The authors queried 5605 advanced/metastatic breast cancers (mBC) to uncover the frequency of ERBB2mut genomic alterations. Clinical responses to anti-HER2 therapeutics were identified. DNA was extracted from 40 µm of formalin-fixed paraffin-embedded (FFPE) sections. Comprehensive genomic profiling (CGP) was used to evaluate up to 315 genes (592× mean coverage depth). Results were analyzed for base substitutions, short indels, copy number changes, and selected rearrangements. Of 5605 cases, 698 (12.5%) featured ERBB2 alterations, including 596 (10.6%) ERBB2 amplifications (ERBB2amp) and 138 (2.4%) ERBB2mut; 38 cases (0.7%) had co-occurring ERBB2amp and ERBB2mut. ERBB2mut predominantly affected the kinase (124 cases; 90%) or extracellular (15 cases; 11%) domains. Both primary BC (52 cases; 38%) and metastatic site biopsies (86 cases; 62%) were found to harbor ERBB2mut, which were distributed across carcinoma not otherwise specified (NOS) (69 cases; 50%), invasive ductal carcinoma (IDC) (40 cases; 29%), invasive lobular carcinoma (ILC) (27 cases; 20%), and mucinous mBC (2 cases; 1%). Genes commonly coaltered with ERBB2 were tumor protein 53 (TP53) (49%); phosphatidylinositol 3-kinase catalytic subunit alpha (PIK3CA) (42%); cadherin 1, type 1 (CDH1) (37%); MYC (17%); and cyclin D1 protein (CCND1) (16%). CDH1 mutations were enriched in ERBB2mut mBC (P<0.0006) and associated with recurrent mBC. Selected patients with ERBB2mut, without ERBB2amp, who responded to anti-HER2 targeted therapies are presented herein. Within this large series, 1.8% of cases harbored ERBB2mut, which are undetectable by standard-of-care IHC or FISH tests. Metastatic BC driven by ERBB2mut respond to anti-HER2 targeted therapies, and expanding clinical trials designed to detect ERBB2mut by CGP and optimize targeted treatments are warranted. Cancer 2016. © 2016 American Cancer Society. Cancer 2016;122:2654-2662. © 2016 American Cancer Society.
27284958	0	16	Nonamplification	T033	C0243095
27284958	17	22	ERBB2	T028	C0242957
27284958	23	42	genomic alterations	T045	C0596611
27284958	51	56	cases	T169	C0868928
27284958	60	69	recurrent	T191	C0278493
27284958	74	98	metastatic breast cancer	T191	C0278488
27284958	128	137	anti-HER2	T033	C0243095
27284958	138	156	targeted therapies	T061	C3854476
27284958	169	185	nonamplification	T033	C0243095
27284958	186	191	ERBB2	T028	C0242957
27284958	192	201	mutations	T045	C0596611
27284958	203	211	ERBB2mut	T028	C0678941
27284958	233	253	immunohistochemistry	T060	C0021044
27284958	255	258	IHC	T060	C0021044
27284958	263	297	fluorescence in situ hybridization	T063	C0162789
27284958	299	303	FISH	T063	C0162789
27284958	326	340	DNA sequencing	T059	C1294197
27284958	357	375	clinical responses	T033	C4055223
27284958	379	417	human epidermal growth factor receptor	T116,T126,T192	C1702024
27284958	419	423	HER2	T116,T126,T192	C1702024
27284958	426	442	targeted therapy	T061	C3854476
27284958	469	503	advanced/metastatic breast cancers	T191	C0278488
27284958	505	508	mBC	T191	C0278488
27284958	525	534	frequency	T079	C0439603
27284958	538	546	ERBB2mut	T028	C0678941
27284958	547	566	genomic alterations	T045	C0596611
27284958	568	586	Clinical responses	T033	C4055223
27284958	590	599	anti-HER2	T033	C0243095
27284958	600	612	therapeutics	T061	C0087111
27284958	618	628	identified	T080	C0205396
27284958	630	633	DNA	T114,T123	C0012854
27284958	662	710	formalin-fixed paraffin-embedded (FFPE) sections	T024	C2711483
27284958	712	743	Comprehensive genomic profiling	T059	C0022885
27284958	745	748	CGP	T059	C0022885
27284958	781	786	genes	T028	C0017337
27284958	815	822	Results	T169	C1274040
27284958	841	859	base substitutions	T045	C1158746
27284958	861	873	short indels	T045	C1956002
27284958	875	894	copy number changes	T045	C2717926
27284958	900	923	selected rearrangements	T045	C0017287
27284958	933	938	cases	T169	C0868928
27284958	961	966	ERBB2	T028	C0242957
27284958	967	978	alterations	T045	C0596611
27284958	1002	1007	ERBB2	T028	C0242957
27284958	1008	1022	amplifications	T045	C0017256
27284958	1024	1032	ERBB2amp	T045	C0017256
27284958	1049	1057	ERBB2mut	T028	C0678941
27284958	1062	1067	cases	T169	C0868928
27284958	1092	1100	ERBB2amp	T045	C0017256
27284958	1105	1113	ERBB2mut	T028	C0678941
27284958	1115	1123	ERBB2mut	T028	C0678941
27284958	1151	1157	kinase	T116,T126	C0031727
27284958	1163	1168	cases	T169	C0868928
27284958	1178	1191	extracellular	T026	C0521119
27284958	1208	1215	domains	T082	C1517050
27284958	1222	1232	primary BC	T191	C0678222
27284958	1237	1242	cases	T169	C0868928
27284958	1253	1268	metastatic site	T033	C0280457
27284958	1269	1277	biopsies	T060	C0005558
27284958	1282	1287	cases	T169	C0868928
27284958	1315	1323	ERBB2mut	T028	C0678941
27284958	1355	1364	carcinoma	T191	C0007097
27284958	1399	1404	cases	T169	C0868928
27284958	1412	1437	invasive ductal carcinoma	T191	C1134719
27284958	1439	1442	IDC	T191	C1134719
27284958	1448	1453	cases	T169	C0868928
27284958	1461	1487	invasive lobular carcinoma	T191	C0279565
27284958	1489	1492	ILC	T191	C0279565
27284958	1498	1503	cases	T169	C0868928
27284958	1515	1527	mucinous mBC	T191	C1334807
27284958	1531	1536	cases	T169	C0868928
27284958	1543	1548	Genes	T028	C0017337
27284958	1573	1578	ERBB2	T028	C0242957
27284958	1584	1600	tumor protein 53	T028	C0079419
27284958	1602	1606	TP53	T028	C0079419
27284958	1615	1668	phosphatidylinositol 3-kinase catalytic subunit alpha	T028	C1335212
27284958	1670	1676	PIK3CA	T028	C1335212
27284958	1685	1703	cadherin 1, type 1	T028	C0694872
27284958	1705	1709	CDH1	T028	C0694872
27284958	1718	1721	MYC	T028	C0086661
27284958	1733	1750	cyclin D1 protein	T028	C1413172
27284958	1752	1757	CCND1	T028	C1413172
27284958	1766	1770	CDH1	T028	C0694872
27284958	1771	1780	mutations	T045	C0596611
27284958	1798	1806	ERBB2mut	T028	C0678941
27284958	1807	1810	mBC	T191	C0278488
27284958	1826	1841	associated with	T080	C0332281
27284958	1842	1855	recurrent mBC	UnknownType	C0741681
27284958	1866	1874	patients	T101	C0030705
27284958	1880	1888	ERBB2mut	T028	C0678941
27284958	1898	1906	ERBB2amp	T045	C0017256
27284958	1925	1934	anti-HER2	T033	C0243095
27284958	1935	1953	targeted therapies	T061	C3854476
27284958	2010	2015	cases	T169	C0868928
27284958	2025	2033	ERBB2mut	T028	C0678941
27284958	2061	2077	standard-of-care	T061	C2936643
27284958	2078	2081	IHC	T060	C0021044
27284958	2085	2095	FISH tests	T063	C0162789
27284958	2097	2110	Metastatic BC	T191	C0278488
27284958	2121	2129	ERBB2mut	T028	C0678941
27284958	2141	2150	anti-HER2	T033	C0243095
27284958	2151	2169	targeted therapies	T061	C3854476
27284958	2185	2200	clinical trials	T062	C0008976
27284958	2220	2228	ERBB2mut	T028	C0678941
27284958	2232	2235	CGP	T059	C0022885
27284958	2249	2268	targeted treatments	T061	C3854476